BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 8984537)

  • 1. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of mono-antibiotic therapy using piperacillin associated with sulbactam and possibly followed by vancomycin in febrile neutropenia in solid tumors].
    Abs L; Kattan J; Culine S; Bekradda M; Farhat F; Droz JP
    Bull Cancer; 1994 Oct; 81(10):871-6. PubMed ID: 7734770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
    Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP
    Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
    Bosseray A; Nicolini F; Brion JP; Michallet M; Hollard D; Stahl JP; Micoud M
    Pathol Biol (Paris); 1992 Oct; 40(8):797-804. PubMed ID: 1484739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
    Böhme A; Shah PM; Stille W; Hoelzer D
    Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
    D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
    Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
    Paganini H; Gómez S; Ruvinsky S; Zubizarreta P; Latella A; Fraquelli L; Iturres AS; Casimir L; Debbag R
    Cancer; 2003 Apr; 97(7):1775-80. PubMed ID: 12655535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of teicoplanin in neutropenic patients: values and limits].
    Espinouse D; Chomarat M
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.